Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 10, 2015 12:08 PM ET


Company Overview of Advanced Accelerator Applications S.A.

Company Overview

Advanced Accelerator Applications S.A., a radiopharmaceutical company, develops, produces, and commercializes molecular nuclear medicine diagnostic and therapeutic products primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany, and Canada. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company...

20 Rue Diesel

Saint Genis Pouilly,  01630


Founded in 2002

360 Employees


33 4 50 99 30 70


33 4 50 99 30 71

Key Executives for Advanced Accelerator Applications S.A.

Founder, Chief Executive Officer, President, Director and Member of R & D Steering Committee
Age: 49
Group Chief Financial Officer
Age: 52
Chief Operating Officer
Age: 57
Global Head of Pre-Clinical Research
Age: 57
Head of Clinical Development
Age: 60
Compensation as of Fiscal Year 2015.

Advanced Accelerator Applications S.A. Key Developments

Advanced Accelerator Eyes Acquisitions

Advanced Accelerator Applications S.A. is looking for acquisition opportunities. Advanced Accelerator has filed an initial public offering (IPO) in the amount of $75 million. Advanced Accelerator intend to use the net proceeds from this offering for expanding our marketing, manufacturing and commercialization capabilities for Lutathera, if it is approved by the FDA and/or EMA and organizing distribution to additional markets and geographies, in particular in the United States, clinical trials and other R&D efforts for our other principal pipeline product candidates, including Annexin V-128, and our Somakit products, expanding our manufacturing infrastructure and for general corporate purposes, including acquisitions of, or investment in businesses or assets to expand any of the above.

Advanced Accelerator Applications S.A. Announces Positive Results from Phase 3 Study NETTER-1 Evaluating Lutathera in Patients with Advanced Midgut Neuroendocrine Tumors

Advanced Accelerator Applications S.A. announced that the pivotal Phase 3 NETTER-1 study for Lutathera (177Lu-DOTATATE) met its primary endpoint of assessing progression-free survival (PFS), demonstrating that Lutathera significantly improved PFS when compared with Sandostatin LAR 60mg (Octreotide LAR) in patients with advanced midgut neuroendocrine tumors (NETs). The NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera was associated with a statistically significant and clinically meaningful risk reduction of 79% of disease progression or death versus a treatment with a double dose of Octreotide LAR (hazard ratio 0.21, 95% CI: 0.13-0.34; p<0.0001). The median PFS in the Lutathera arm is not yet reached, whilst the median PFS in the Octreotide LAR 60 mg arm was 8.4 months. The adverse events observed on Lutathera in NETTER-1 are consistent with the results of Lutathera's previous Phase I-II study, with Lutathera demonstrating a favorable safety profile. Enrollment was completed in February 2015, with a target of 230 patients randomized (1:1) in 36 sites in Europe and 15 sites in the United States. At the time of statistical analysis, the number of centrally confirmed disease progressions or deaths was 23 in the Lutathera group and 67 in the Octreotide LAR 60 mg group. The median PFS was not yet reached for Lutathera and was 8.4 months with 60 mg Octreotide LAR [95% CI: 5.8-11.0 months], p<0.0001, with a hazard ratio of 0.21 [95% CI: 0.13-0.34]. Within the current evaluable patient dataset for tumor responses (n=201), 19 patients (19%) reported complete and partial responses (CR+PR) in the Lutathera group versus 3 (3%) in the Octreotide LAR 60 mg group (p<0.0004). Although the overall survival (OS) data is not mature enough for a definitive analysis, the number of deaths was 13 in the Lutathera group and 22 in the Octreotide LAR 60 mg group (p<0.0186 at interim analysis), which initially suggests an improvement in OS. The Phase 3 NETTER-1 study provides evidence of a clinically meaningful and statistically significant increase in PFS and objective response rate (ORR), and also suggests a survival benefit in patients with advanced midgut neuroendocrine tumors treated with Lutathera.

Advanced Accelerator Applications S.A. Presents at Citi European Healthcare Conference, Jun-15-2015

Advanced Accelerator Applications S.A. Presents at Citi European Healthcare Conference, Jun-15-2015 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Jordan Silverstein, Director of Investor Relations.

Similar Private Companies By Industry

Company Name Region
Splicos SAS Europe
Novalyst Discovery SAS Europe
Biomethodes SA Europe
Orega Biotech SAS Europe
Wittycell Europe

Recent Private Companies Transactions

Private Placement
June 23, 2015
January 8, 2015
AAA Canada

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advanced Accelerator Applications S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at